Lantheus Holdings, Inc. Profile Avatar - Palmy Investing

Lantheus Holdings, Inc.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound en…
Drug Manufacturers - Specialty & Generic
US, North Billerica [HQ]
Financials

Analysts

Earnings
Reported
Past Estimate Consensus
Future Estimate Consensus
EPS Revenue EBITDA EBIT SGA
FY EPS Revenue [mil.] Profit [mil.] EBITDA [mil.] EBIT [mil.] Expenses · SGA [mil.]
E E E E E E
All monetary values are presented in USD ($). E stands for Estimate.
2015 - 0.438 - 293 - 30 - 18 - 0.00 - 93
2016 -0.6000 0.658 293 298 -14 25 42 68 42 52 78 70
2017 0.8400 1.093 301 327 26 145 50 72 50 46 75 85
2018 3.3100 0.850 331 340 123 30 60 61 51 49 92 71
2019 1.0600 1.127 343 348 40 27 66 48 64 45 93 87
2020 0.8100 0.454 347 337 31 -30 45 51 51 -11 103 212
2021 -0.2500 0.413 339 407 -13 6 -2 127 -4 50 110 308
2022 -1.0600 3.836 425 916 -71 33 -83 97 -76 65 218 187
2023 0.4100 5.920 935 1,281 28 428 34 96 36 61 233 204
2024 4.7900 6.665 1,296 1,519 326 468 444 93 364 0.02 267 483
2025 - 7.201 - 1,656 - 502 - 102 - 0.03 - 527
2026 - 8.324 - 1,919 - 2.F11X/td> - 2.F111/td> - 2.F111 - 2.F111
2027 - 10.079 - 2,330 - 1.F12X/td> - 1.F121/td> - 1.F121 - 1.F121
2028 - 12.663 - 2,905 - 0.F13X/td> - 0.F131/td> - 0.F131 - 0.F131
Institutional Sentiment
Morgan Stanley
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
JP Morgan Chase
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Citigroup
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Overall Consensus
Grading Consensus
Click to each, to see the grade
Price Target Consensus

-59.688% $54.03 · MISS

Nov. 6, 2024
Price Then
$114.96
Price Target
$144.55
Price Now
$90.52
End of LNTH's Analysis
CIK: 1521036 CUSIP: 516544103 ISIN: US5165441032 LEI: - UEI: -
Secondary Listings
LNTH has no secondary listings inside our databases.